Clinical paper

Intramuscular adrenaline for out-of-hospital cardiac arrest is associated with faster drug delivery: A feasibility study

A.E. Pugh a,*, H.H. Stoecklein a,b, J.E. Tonna a,c, G.L. Hoareau a,d, M.A. Johnson a, S.T. Youngquist a,b

a Division of Emergency Medicine, Division of Surgery, University of Utah School of Medicine, 30 North 1900 East, Room 1C26 SOM, Salt Lake City, UT 84132, USA
b Salt Lake City Fire Department, Salt Lake City, UT, USA
c Division of Cardiothoracic Surgery, University of Utah School of Medicine, UT, USA
d Nora Eccles Harrison Cardiovascular Research and Training Institute, USA

Abstract

Background: Early adrenaline administration is associated with return of spontaneous circulation (ROSC) and survival in out-of-hospital cardiac arrest (OHCA). Animal data demonstrate a similar rate of ROSC when early intramuscular (IM) adrenaline is given compared to early intravenous (IV) adrenaline.

Aim: To evaluate the feasibility of protocolized first-dose IM adrenaline in OHCA and it’s effect on time from Public Safety Access Point (PSAP) call receipt to adrenaline administration when compared to IO and IV administration.

Methods: This is a before-and-after feasibility study of adult OHCAPs in a single EMS service following adoption of a protocol for first-dose IM adrenaline. Time from PSAP call to administration and outcomes were compared to 674 historical controls (from January 1, 2013 – February 8, 2021) who received at least one dose of adrenaline by IV or IO routes.

Results: During the study period, first-dose IM adrenaline was administered to 99 patients (December 1, 2019 – February 8, 2021). IM adrenaline was given a median of 12.2 min (95% CI 11.4 – 13.1 min) after the PSAP call receipt compared to 15.3 min for the IV route (95% CI 14.6 – 16.0 min) and 15.3 min for the IO route (95% CI 14.9 – 15.7 min) with a time savings of 3 min (95% CI 2 – 4 min). Rates of survival to hospital discharge appeared similar between groups: 10% for IM, 8% for IV and 7% for IO. However, results related to survival were underpowered for statistical comparison.

Conclusions: Within the limitations of a small sample size and before-and-after design, first-dose IM adrenaline was feasible and reduced the time to adrenaline administration.

Keywords: Out-of-hospital cardiac arrest (OHCA), Intramuscular adrenaline

Abbreviations: AHA, American Heart Association; CPR, cardiopulmonary resuscitation; CQI, Care Quality Improvement; EMS, Emergency Medical Services; IM, intramuscular; IO, intraosseous; IRB, Institutional Review Board; IV, intravenous; OHCA, Out of hospital cardiac arrest; PSAP, Public Safety Access Point; ROSC, return of spontaneous circulation; SLCFD, Salt Lake City Fire Department; TXA, tranexamic acid.
* Corresponding author.
E-mail address: Andrew.pugh@hsc.utah.edu (A.E. Pugh).
http://dx.doi.org/10.1016/j.resplu.2021.100142
Received 24 February 2021; Received in revised form 13 May 2021; Accepted 23 May 2021
Available online xxx
Background

Guidelines from the American Heart Association (AHA) recommend adrenaline administration as soon as is reasonably possible in out-of-hospital cardiac arrest (OHCA) from non-shockable rhythms. The optimal timing of adrenaline administration to treat shockable rhythms is less clear; observational evidence suggests that early adrenaline administration is positively associated with return of spontaneous circulation (ROSC) and survival in OHCA.7–8

In OHCA, intravenous (IV) and intraosseous (IO) access is not always immediately available and attempts at difficult access may distract from quality chest compressions and timely defibrillation.9 Intramuscular (IM) adrenaline is already widely accepted as a safe and rapid lifesaving treatment in anaphylaxis, even in the hands of nonprofessionals.10–14 It may therefore represent a promising route of administration since adrenaline could be administered to patients with OHCA early and without difficulty. There are currently limited available data on the use of IM adrenaline in cardiac arrest. In a porcine model, early IM adrenaline demonstrated similar survival compared with early IV adrenaline, and superior survival compared to delayed IV adrenaline.15

This study investigates the feasibility of rapid IM adrenaline delivery in OHCA in an urban EMS system. In other words, we sought to answer the question, “Can an intramuscular route of administration feasibly decrease the time from PSAP to adrenaline delivery in out-of-hospital cardiac arrest?” We hypothesized that IM adrenaline would reduce the time from Public Safety Access Point (PSAP) call receipt to adrenaline administration when compared to IO and IV administration.

Methods

This study was approved by the Institutional Review Board at the University of Utah (IRB # IRB_00076654).

Study design and setting

This is an observational analysis of IM administration of adrenaline to treat OHCA. The administration of IM adrenaline was done as part of a change in clinical care for patients with OHCA, as detailed in Interventions. The Salt Lake City Fire Department (SLCFD) is a two-tiered, fire-based municipal agency that serves an urban corridor and international airport with a daytime population of approximately 315,000. EMS calls are prioritized and dispatched by a public safety answering point (911) that employs Medical Priority Dispatch System (MPDS, Salt Lake City, UT) protocols to determine acuity and level of response (BLS vs ALS). Calls identified as cardiac arrest are prioritized to the nearest available BLS or ALS unit with a trailing ALS unit if this was not first on scene. Cardiac arrests typically involve 6–10 providers on scene.

Selection of participants

All adult patients with OHCA between December 1, 2019 and February 8, 2021 were eligible for inclusion in the feasibility cohort if they received a shock by a public or first responder automated external defibrillator (AED) or chest compressions by EMS personnel and remained in arrest after the first rhythm analysis. These were compared to historical patients treated for OHCA from January 1, 2013 through November 30, 2019 (and concurrent patients who did not get IM adrenaline according to the new protocol). All controls received a first dose of adrenaline by the IV or IO route at the discretion of the providers on scene. Since 2011, as part of provider training, we have emphasized early IO access in OHCA patients (tibial site only), based on the results of studies showing more rapid vascular access with IO.15 However, the initial route of delivery was left to the discretion of the providers on scene. During the study period, the route of subsequent doses of adrenaline following IM administration was also left to provider discretion. We excluded children <18 years of age, drownings, strangulation, and traumatic causes of arrest from the treatment protocol and analysis. We also excluded patients who achieved return of spontaneous circulation (ROSC) prior to ALS care, EMS witnessed arrests, arrests in which no adrenaline was administered or in which it was given via endotracheal tube, and when it was given by healthcare providers prior to EMS arrival. We also excluded patients for whom outcome data was missing.

Interventions

The administration of IM adrenaline was protocolized in clinical care guidelines on December 1, 2019 for all patients meeting criteria for standard adrenaline by international guidelines. Paramedics were trained to deliver 5 mg of adrenaline at a concentration 1 mg/mL (5 mL) to the lateral thigh. This approach was familiar to paramedics as they routinely deliver a lower dose of the medication by the IM route for the treatment of anaphylaxis. Subsequent doses of adrenaline at standard ALS dosing (1 mg/dose) were administered by the intravenous or intraosseous route if necessary. The IV route was preferred, if possible, for subsequent medication administration.

Outcome measurements

Since 2009, SLCFD has reported Utstein data along with hospital outcomes on all cardiac arrests to a statewide registry (Cardiac Arrest Registry to Enhance Survival [CARES]). Cardiac arrests were identified by the medical director (SY) through periodic review of electronic patient care reports (ImageTrend, Roseville, MN) for encounters in which the primary or secondary impression of the paramedics is cardiac or respiratory arrest. Discovery of OHCA cases were cross-checked with a standardized query that identifies all encounters in which CPR was performed, a shock was delivered, or adrenaline was administered. We obtained hospital outcomes, including neurologic status at discharge, through hospital record review or correspondence with a hospital liaison. Paramedics were trained to enter the timing of adrenaline administration and all interventions in a flow sheet in the patient care report and it is from these records that timing data has been abstracted since 2013. When timing was missing, the timing was recorded as missing for purposes of analysis.

Outcomes

The primary outcome of this analysis is the time from PSAP (911) call receipt to adrenaline administration comparing the IM to IV and IO routes. The time of PSAP call receipt is routinely imported into the electronic patient care report from computer aided dispatch software from whence we abstracted times. We chose this outcome as the protocol was designed to assess the feasibility of IM administration and any time savings, when compared to alternative routes of
administration. Secondary outcomes include cumulative adrenaline dose, low flow time (defined as time from first ALS compression to ROSC), the proportion of OHCA's achieving ROSC, survival to hospital discharge, and survival to hospital discharge with good neurologic function, defined as a cerebral performance category (CPC) score of 1 or 2. We routinely obtained outcomes in a non-blinded fashion.

**Analysis**

All data were collected and managed using an online database (REDCap electronic data capture tools hosted at the University of Utah).17 We downloaded data in native Stata format for analysis using Stata/IC 14.2 for Mac (64-bit Intel, StatCorp, College Station, TX). In this report, we provide summary measures of demographic and resuscitation variables, along with secondary outcomes, appropriate to the underlying distribution. We performed linear regression to estimate the average time from PSAP to adrenaline administration in minutes and compare differences in average time between IM, IO, IV. Chi-Square and Fisher’s exact tests were performed to compare proportions. Comparison of median low flow times between IM, IV, and IO groups was performed using a Kruskal Wallis test. We considered a p value <0.05 to be statistically significant for all statistical comparisons.

**Results**

**Characteristics of study subjects**

During the period of interest, resuscitation was attempted for 961 OHCA's. After exclusions, 773 subjects administered adrenaline were available for analysis (Fig. 1): 518 cases of initial dose of adrenaline via intravenous administration, 156 cases of initial dose of adrenaline via intravenous administration, and 99 cases of initial dose of adrenaline via intramuscular administration. Demographic and key resuscitation variables are given in Table 1.

**Main results**

Box plots for the distribution of time from PSAP call to adrenaline administration are given in Fig. 2. Timing of adrenaline administration was missing for 3/99 (3%) cases of IM administration, 5/156 (3%) IV cases, and 19/518 (4%) IO cases. When given via the IM route, adrenaline was administered a mean of 12.2 min (95% CI 11.4 – 13.1 min) from PSAP call receipt, compared to means of 15.3 min (95% CI 14.6 – 16.0 min) and 15.3 min (95% CI 14.9 – 15.7 min), respectively via IV and IO routes. The difference between IM and IO and IV was the same when rounded to the minute: 3 min (95% CI 2 – 4 min, p < 0.0001).

The average time from scene arrival to adrenaline administration was 5.9 min (95% CI 5.1 – 6.6 min) for IM cases, 8.6 min (95% CI 8.0 – 9.2 min) for IV cases, and 8.6 min (95% CI 8.3 – 8.9 min) for IO cases. The difference between IM and IV was 2.7 min (95% CI 1.7 – 3.7 min) and the difference between IM and IO was 2.7 min (95% CI 1.9 – 3.6 min, p < 0.0001).

**Secondary outcomes**

Secondary outcomes, including low flow time, ROSC and survival are provided in Table 2. None of these comparisons showed statistically significant differences.

**Discussion**

Early administration of adrenaline in OHCA has been associated with increased rates of ROSC, survival to hospital discharge and favorable neurological outcome.3,5,8,18 – 20 The current study demonstrates that adrenaline delivered by paramedics via the IM route is feasible and leads to earlier administration when compared to IV and IO administration. Rates of ROSC and survival were similar to historical rates of such for IO and IV routes of administration, but this feasibility study was underpowered to detect small differences in patient-oriented outcomes and the before-and-after design is vulnerable to temporal trends.

Faster time to drug administration with intramuscular delivery makes intuitive sense. Intravenous access can be challenging, especially in a patient in cardiac arrest, and establishing intravenous access is more time consuming than the delivery of a single intramuscular injection. Furthermore, prehospital providers are already familiar with IM administration as a treatment for anaphylaxis, making its administration in OHCA an easily transferrable skill with only a difference in dosing and indication. Intramuscular compared with IV drug administration has the advantage of a reduced plasma peak concentration and a prolonged duration of action in the patient in anaphylactic shock.15,21 This could potentially decrease the need for redosing, subsequently mitigating task fatigue and distraction from quality CPR in OHCA. However, the pharmacokinetics of IM administration during cardiac arrest are currently unclear.

Whether the slower onset, lower peak concentration, and longer duration of action of IM administration confer physiologic and neuroprotective benefit is not known. Studies of cerebral perfusion during cardiac arrest have shown incrementally decreased effectiveness of successive adrenaline boluses over time.22,23 In comparing bolus dosing versus continuous infusion of adrenaline during cardiac arrest, studies have shown conflicting results. Nosrati et al. showed transient increases in cerebral perfusion with bolus but not continuous adrenaline dosing whereas Johansson et al. showed significantly higher cerebral perfusion with continuous compared to bolus dosing.22,24 While IM pharmacokinetics may be more similar to continuous IV dosing than bolus IV dosing, no studies exist with
Table 1 - Demographic and key resuscitation variables for 773 OHCA in which adrenaline was administered, according to route of first dose.

|                      | IM (n = 99) | IO (n = 518) | IV (n = 156) |
|----------------------|-------------|--------------|--------------|
| Age (SD)             | 61 (17)     | 60 (16)      | 61 (18)      |
| Female gender        | 33 (33%)    | 161 (31%)    | 39 (25%)     |
| Race/ethnicity       |             |              |              |
| Caucasian            | 57 (58%)    | 315 (61%)    | 101 (65%)    |
| Hispanic/Latino      | 13 (13%)    | 55 (11%)     | 15 (10%)     |
| Black/African American| 3 (3%)      | 26 (5%)      | 3 (2%)       |
| Asian                | 3 (3%)      | 6 (1%)       | 4 (3%)       |
| Hawaiian/Pacific Islander | 3 (3%)    | 28 (5%)      | 7 (4%)       |
| Native American      | 2 (2%)      | 14 (3%)      | 1 (1%)       |
| Unknown              | 18 (18%)    | 74 (14%)     | 25 (16%)     |
| Public location of arrest | 36 (36%)  | 171 (33%)    | 46 (29%)     |
| Arrest witnessed     | 49 (49%)    | 242 (47%)    | 84 (54%)     |
| Bystander CPR        | 71 (72%)    | 317 (61%)    | 98 (63%)     |
| Bystander shock      | 1 (1%)      | 15 (3%)      | 6 (4%)       |
| Initial rhythm       |             |              |              |
| VF/VT                | 27 (27%)    | 136 (26%)    | 39 (25%)     |
| PEA                  | 17 (17%)    | 92 (18%)     | 26 (17%)     |
| Asystole             | 40 (40%)    | 224 (43%)    | 65 (42%)     |
| Unknown non-shockable| 15 (15%)    | 66 (13%)     | 26 (17%)     |
| EMS response interval (min, SD) | 6.3 (1.8) | 6.5 (2.1)   | 6.4 (2.3)   |
| CPR metrics          |             |              |              |
| Rate (cpm, SD)       | 112 (7)     | 110 (8)      | 111 (8)      |
| Depth (cm, SD)       | 6 (1)       | 6 (1)        | 6 (1)        |
| Chest compression fraction (SD) | 83 (11) | 92 (7)      | 91 (8)      |
| Advanced airway placed | 90 (92%)  | 456 (88%)    | 127 (81%)    |
| Cumulative adrenaline doses (SD) | 3 (1)     | 3 (1)        | 3 (1)        |
| Duration of resuscitation before field termination (min, IQR) | 23 (20–29) | 26 (19–33) | 28 (20–33) |

comparisons of IM and either continuous or bolus dosed IV adrenaline. Furthermore, all of this data is derived from animal studies and studies evaluating these questions in humans are not available to our knowledge.

In a porcine model comparing early IV adrenaline, early IM adrenaline and delayed IM adrenaline administration, early IM adrenaline resulted in similar survival compared with early IV adrenaline and was superior to delayed IV adrenaline. In this porcine model, time to ROSC was, on average, 2 min faster in the IV compared to IM group (2 versus 4 min). Our study showed even greater mean differences in time to ROSC (low flow time) between IM and IV (4 min) and between IM and IO (6 min) groups, although these differences did not reach statistical significance. Even a 1-min delay in time to adrenaline administration may be enough to significantly reduce survival in OHCA, according to models. Thus the time saved in medication administration and the decrease in low flow times observed here suggest a potentially significant possible benefit to IM administration.

The PARAMEDIC2 trial, published in 2018, demonstrated higher 30-day survival in the cohort randomized to adrenaline (3.2%) when compared to placebo (2.4%), albeit with a greater proportion of survivors discharged with severe neurologic deficits in the adrenaline group (31% vs 18%). In PARAMEDIC2, the median interval between emergency call and administration of trial drug was just over 21 min (IQR 16–27), with an EMS response interval of 6.6–6.7 min. It is possible that this prolonged interval between arrest and adrenaline administration mitigated the potential benefit of adrenaline in that study population. It is also possible that adrenaline administration during a later physiologic phase of cardiac arrest is more neurologically harmful than during earlier phases of cardiac arrest physiology. Despite a similar EMS response interval (6.2–6.5 min), our cohorts received adrenaline earlier than those in the PARAMEDIC2 trial, with a median (IQR) time from emergency call to first dose of 12 min (10–14 min) for IM adrenaline, 15 min (12–18 min).

Fig. 2 – Box plot distributions for time from PSAP call to adrenaline administration in 773 OHCA cases in Salt Lake City, Utah categorized by route of first dose. Timing of administration was missing for 3/99 cases of IM administration, 5/156 IV cases, and 19/518 IO cases.
for IV and IO adrenaline. We observed higher survival to hospital discharge in our cohort (as high as 9% in the IM adrenaline group) compared to that in the PARAMEDIC2 trial. The reason for earlier administration of adrenaline (via IV and IO routes) compared to Paramedic 2 after arrival on scene is unclear, although we speculate that this reflects differences in team configuration; SLCFD employs a pit crew approach to resuscitation, typically with 6–10 providers on scene, with immediate actionable items, such as establishing IV or IO access, assigned to individual team members upon arrival.

In a post-hoc analysis of trial data, the PARAMEDIC2 investigators found a time-dependent decrease in the probabilities of ROSC and survival in both arms. The probability of ROSC was higher in a statistically significant and time-dependent fashion in the adrenaline arm throughout the resuscitation interval. Likelihoods of 30-day survival and survival with good neurologic function were, on average, higher for the adrenaline group up until approximately the 25 and 20 min points in the resuscitation attempt, respectively, after which rates of both were similar between groups. These early benefits for survival with adrenaline were not, in contrast to ROSC, statistically significant.

We believe ours is the first study to evaluate the use of protocolized intramuscular adrenaline in OHCA. However, the use of IM drug administration versus IV administration has been studied previously in other time-sensitive conditions such as status epilepticus, anaphylaxis and trauma. Silbergel et al. demonstrated faster median time to drug delivery for IM Midazolam versus IV Lorazepam in prehospital status epilepticus while non-inferiority for their primary outcome of time to seizure cessation. Furthermore, Grassin-Delyle et al. demonstrated safety and a comparable pharmacokinetic profile for IM compared to IV Tranexamic Acid (TXA) in adult trauma patients. These prior studies confirm the notion of superior time to delivery with IM drug delivery without deleterious effects on patient outcomes. Our current study is not powered to compare meaningful patient orientated outcomes at this stage, thus signifying the need for a large, randomized trial.

**Implications**

OHCA is a leading cause of mortality worldwide. In the US, the estimated incidence is 55 per 100,000 person years, with a reported percentage survival to hospital discharge of 6.8%. Regional variations in reporting and survival mean the exact burden of OHCA to public health is unknown, however even within the United States, substantial regional variations in the management of OHCA and survival are known to exist. In tiered systems where BLS providers arrive on scene long before ALS providers or in systems that are ALS only, adrenaline administration may be quite delayed or impossible. If safety and efficacy of early paramedic administration of IM adrenaline for OHCA can be established, then expanding scope of practice to allow BLS providers to administer IM adrenaline for OHCA may have significant impacts on survival in these systems. Furthermore, in countries with rudimentary prehospital systems, or with no prehospital infrastructure at all, where rapid IV adrenaline delivery may be even more challenging, survival is likely to be even less than the estimates above. It is possible that IM adrenaline could be given by trained first responders and even untrained bystanders, with important reductions in time to treatment. Ideally, prompt treatment would be further facilitated by the development of an easy-to-use auto- injector or pre-filled syringes. Finally, the optimal IM dose is an area needing further research.

**Limitations**

This study has several limitations, including a small sample size and a before-and-after comparison with controls. The study is observational by design, evaluating response times before and after a protocol change. The data and results are therefore subject to potential bias from unmeasured and uncontrolled confounders and temporal trends, and the reader should be cautioned from over interpretation. However, given that dispatch protocols and team configuration have remained stable over the study period, we feel that the results likely represent a true benefit in time to delivery of adrenaline in OHCA. The cardiac arrests of a majority of patients treated with IM adrenaline occurred during periods of widespread local infection from the worldwide COVID-19 pandemic. Multiple other communities have reported lower survival from OHCA during the pandemic, including a 17% reduction in survival in U.S. communities reporting to the CARES registry and even a 50% reduction in survival to discharge in one Australian study. It is unclear how IM adrenaline interacted with competing risks such as COVID-19 in our cohort, although we have not observed a decrease in survival in OHCA patients during the pandemic (most of whom received IM adrenaline) compared to pre-pandemic survival rates in

---

Table 2 – Outcomes for 773 OHCA’s in which adrenaline was administered, according to route of first-dose administration. Differences were not statistically significant.

| Route   | Any return of spontaneous circulation (ROSC) | Survival to hospital discharge | Survival to hospital discharge with CPC 1–2 | Low flow time* (min, IQR) |
|---------|---------------------------------------------|-------------------------------|------------------------------------------|-------------------------|
| IM (n = 99) | 39 (39%) | 66 (67%) | 7 (7%) | 13 (8–22) |
| IO (n = 518) | 214 (41%) | 354 (68%) | 32 (6%) | 17 (10–30) |
| IV (n = 156) | 65 (42%) | 102 (65%) | 12 (8%) | 15 (11–28) |

* Defined as time from first ALS compression to ROSC as abstracted retrospectively from defibrillator/monitor data.
our system. The impact of the pandemic on time to adrenaline administration is unclear. During the study period, which included a large period of pandemic effects, providers would don PPE prior to patient contact, which may have increased the time to adrenaline administration during the study period. Additionally, the dose chosen for this investigation is lower than an equipotent intravenous dose, equivalent to approximately 0.5 mg IV. The only other study to directly compare IV and IM dosing of adrenaline to our knowledge used a ten-fold dose difference between IM and IV doses.15 It is possible that a higher dose would be more effective and should be considered for further study.

**Conclusion**

The current study demonstrates that adrenaline delivered by paramedics via the IM route leads to earlier administration when compared to IV and IO administration in OHCA. This study provides evidence that the intervention is feasible and was easily integrated into an urban EMS OHCA care model. A larger randomized trial is needed to assess its effect on patient orientated outcomes.

**Credit author**

All authors have made substantial contributions to all of the following: the conception and design of the study, interpretation of data, drafting the article and revising it critically for important intellectual content. All authors have approved the manuscript for submission. The contents of this manuscript (including tables and figures) have not been published elsewhere.

All authors have made substantial contributions to all of the following: the conception and design of the study, interpretation of data, drafting the article and revising it critically for important intellectual content. All authors have approved the manuscript for submission. The contents of this manuscript (including tables and figures) have not been published elsewhere.

**Approval**

University of Utah IRB # IRB_00076654.

**Funding**

JET is supported by a Career Development Award from the National Institutes of Health/National Heart, Lung, And Blood Institute (K23 HL 141596).

**Conflicts of interest**

JET received speaker fees and travel compensation from LivaNova and Philips Healthcare, unrelated to this work. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

We have no other conflicts of interest to declare.

**References**

1. Panchal AR, Berg KM, Hirsch KG, et al. 2019 American Heart Association focused update on advanced cardiovascular life support: use of advanced airways, vasopressors, and extracorporeal cardiopulmonary resuscitation during cardiac arrest: an update to the American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. Circulation 2019;140: Available from: https://www.ahajournals.org/doi/10.1161/CIR.0000000000007372 [cited 7 September 2020].
2. Nakahara S, Tomio J, Nishida M, Morimura N, Ichikawa M, Sakamoto T. Association between timing of epinephrine administration and intact neurologic survival following out-of-hospital cardiac arrest in Japan: a population-based prospective observational study: timing of epinephrine administration for cardiac arrest. Acad Emerg Med 2012;19:782–92.
3. Tanaka H, Takyu H, Sagisaka R, et al. Favorable neurological outcomes by early epinephrine administration within 19 minutes after EMS call for out-of-hospital cardiac arrest patients. Am J Emerg Med 2016;34:2284–90.
4. Hayashi Y, Iwami T, Kitamura T, et al. Impact of early intravenous epinephrine administration on outcomes following out-of-hospital cardiac arrest. Circ J 2012;76:1639–45.
5. Ueta H, Tanaka H, Tanaka S, Sagisaka R, Takyu H. Quick epinephrine administration induces favorable neurological outcomes in out-of-hospital cardiac arrest patients. Am J Emerg Med 2017;35:676–80.
6. Koscik C, Pinawin A, McGovern H, et al. Rapid epinephrine administration improves early outcomes in out-of-hospital cardiac arrest. Resuscitation 2013;84:915–20.
7. Donnino MW, Salciccioli JD, Howell MD, et al. Time to administration of epinephrine and outcome after in-hospital cardiac arrest with nonshockable rhythms: retrospective analysis of large in-hospital data registry. BMJ 2014;33493028–3028.
8. Hansen M, Schmicker RH, Newgard CD, et al. Time to epinephrine administration and survival from nonshockable out-of-hospital cardiac arrest among children and adults. Circulation 2018;137:2032–40.
9. Berg RA, Sanders AB, Kern KB, et al. Adverse hemodynamic effects of interrupting chest compressions for rescue breathing during cardiopulmonary resuscitation for ventricular fibrillation cardiac arrest. Circulation 2001;104:2465–70.
10. Campbell RL, Belloilo MF, Motosue MS, Sunga KL, Lohse CM, Rudis MI. Autoinjectors preferred for intramuscular epinephrine in anaphylaxis and allergic reactions. West J Emerg Med 2016;17:775–82.
11. Sicherer SH, Simons FER. Section on allergy and immunology. Epinephrine for first-aid management of anaphylaxis. Pediatrics 2017;139:
12. Lieberman PL. Recognition and first-line treatment of anaphylaxis. Am J Med 2014;127:56–11.
13. Wood JP, Traub SJ, Lipinski C. Safety of epinephrine for anaphylaxis in the emergency setting. World J Emerg Med 2013;4:245–51.
14. Jacobsen RC, Millin MG. The use of epinephrine for out-of-hospital treatment of anaphylaxis: resource document for the National Association of EMS Physicians position statement. Prehosp Emerg Care 2011;15:570–6.
15. Mauch J, Ringer SK, Spielmann N, Weiss M. Intravenous versus intramuscular epinephrine administration during cardiopulmonary resuscitation—a pilot study in piglets. Anderson B, editor. Paediatr Anaesth 2013;23:906–12.
16. Mody P, Brown SP, Kudenchuk PJ, et al. Intravenous versus intranasal access in patients with out-of-hospital cardiac arrest: Insights from the resuscitation outcomes consortium continuous chest compression trial. Resuscitation 2019;134:69–75.
17. Harris PA, Taylor R, Minor BL, et al. The REDCap consortium: building an international community of software platform partners. J Biomed Inform 2019;95:103208.
18. Ran L, Liu J, Tanaka H, Hubble MW, Hiroshi T, Huang W. Early administration of adrenaline for out-of-hospital cardiac arrest: a systematic review and meta-analysis. J Am Heart Assoc 2020;9:e014330.

19. Bircher NG, Chan PS, Xu Y, for the American Heart Association’s Get With The Guidelines—Resuscitation Investigators. Delays in cardiopulmonary resuscitation, defibrillation, and epinephrine administration all decrease survival in in-hospital cardiac arrest. Anesthesiology 2019;130:414–22.

20. Ewy GA, Bobrow BJ, Chikani V, et al. The time dependent association of adrenaline administration and survival from out-of-hospital cardiac arrest. Resuscitation 2015;96:180–5.

21. Simons FE, Gu X, Simons KJ. Epinephrine absorption in adults: intramuscular versus subcutaneous injection. J Allergy Clin Immunol 2001;108:871–3.

22. Nosrati R, Lin S, Mohindra R, Ramadeen A, Toronov V, Dorian P. Study of the effects of epinephrine on cerebral oxygenation and metabolism during cardiac arrest and resuscitation by hyperspectral near-infrared spectroscopy. Crit Care Med 2019;47:e349–57.

23. Mavroudis CD, Ko TS, Morgan RW, et al. Epinephrine’s effects on cerebrovascular and systemic hemodynamics during cardiopulmonary resuscitation. Crit Care 2020;24:583.

24. Johansson J, Gedeborg R, Basu S, Rubertsson S. Increased cortical cerebral blood flow by continuous infusion of adrenaline (epinephrine) during experimental cardiopulmonary resuscitation. Resuscitation 2003;57:299–307.

25. Perkins GD, Ji C, Deakin CD, et al. A randomized trial of epinephrine in out-of-hospital cardiac arrest. N Engl J Med 2018;379:711–21.

26. Perkins GD, Kenna C, Ji C, et al. The influence of time to adrenaline administration in the Paramedic 2 randomised controlled trial. Intensive Care Med 2020;46:426–36.

27. Silbergleit R, Durkalski V, Lowenstein D, et al. Intramuscular versus intravenous therapy for prehospital status epilepticus. N Engl J Med 2012;366:591–600.

28. Grassin-Delyle S, Shakur-Still H, Picetti R, et al. Pharmacokinetics of intramuscular tranexamic acid in bleeding trauma patients: a clinical trial. Br J Anaesth 2020.

29. Myat A, Song K-J, Rea T. Out-of-hospital cardiac arrest: current concepts. Lancet 2018;391:970–9.

30. Berdowski J, Berg RA, Tijssen JGP, Koster RW. Global incidences of out-of-hospital cardiac arrest and survival rates: systematic review of 67 prospective studies. Resuscitation 2010;81:1479–87.

31. Rea TD, Eisenberg MS, Sinibaldi G, White RD. Incidence of EMS-treated out-of-hospital cardiac arrest in the United States. Resuscitation 2004;63:17–24.

32. Nichol G, Thomas E, Callaway CW, et al. Regional variation in out-of-hospital cardiac arrest incidence and outcome. JAMA 2008;300:1423–31.

33. Kironji AG, Hodkinson P, de Ramirez SS, et al. Identifying barriers for out of hospital emergency care in low and low-middle income countries: a systematic review, BMC Health Serv Res 2018;18:291.

34. Mould-Millman N-K, Dixon JM, Sefa N, et al. The State of Emergency Medical Services (EMS) systems in Africa. Prehosp Disaster Med 2017;32:273–83.

35. Ball J, Nehme Z, Bernard S, Stub D, Stephenson M, Smith K. Collateral damage: hidden impact of the COVID-19 pandemic on the out-of-hospital cardiac arrest system-of-care. Resuscitation 2020;156:157–63.